New Delhi, March 31 (NationPress) India’s bioeconomy is on the verge of reaching the $200 billion threshold, marking a pivotal moment in its development. A robust policy framework and a burgeoning innovation landscape are indicative of the forthcoming growth phase, as revealed in a recent report.

Prepared by Endiya Partners, the document highlights that the bioeconomy in India has surged from approximately $10 billion in 2014 to over $195 billion by 2026, now accounting for nearly 5 percent of the GDP.

India, long esteemed as the 'Pharmacy of the World' for providing nearly 20 percent of global generics and more than 60 percent of vaccines, is now evolving into an innovation-driven biopharma ecosystem that prioritizes novel therapies and advanced technological platforms.

The report emphasized that India is at a crucial turning point, propelled by favorable policy initiatives, regulatory advancements, and heightened global recognition of its clinical-stage assets.

It also outlined significant governmental initiatives, such as the proposed Rs 10,000 crore Biopharma Shakti scheme and the Rs 1,00,000 crore Research, Development, and Innovation (RDI) Fund, which are expected to catalyze the establishment of a vibrant innovation ecosystem.

Recent regulatory changes, including a streamlined 45-day approval process and pre-intimation pathways, are anticipated to alleviate administrative hurdles and shorten drug development timelines by as much as four months.

Concurrently, shifts within the global biopharma landscape, such as rising R&D expenses, estimated at $2.2 billion per asset, and an impending $300 billion patent cliff, are creating avenues for cost-effective and accelerated research ecosystems like India.

The report indicated that Indian biotech startups enjoy a competitive edge dubbed 'Recruitment Alpha,' which facilitates significantly faster patient recruitment, allowing drug candidates to progress to Phase II trials at considerably lower costs than their international counterparts.

This benefit enables Indian companies to pursue multiple drug development paths simultaneously, thereby enhancing overall success rates.

Nevertheless, the report also pointed out existing challenges, including deficiencies in pilot-scale GMP infrastructure, a lack of late-stage funding, shortages of skilled personnel, and a pressing need for enhanced translational research capabilities.

Despite these challenges, India's biopharma ecosystem, which includes over 2,500 startups, about 100 incubators, and more than 600 research institutes, is well-equipped to foster the next growth phase.

"With continuous policy backing and intensified collaboration within the ecosystem, India is poised to become a global hub for cost-efficient and high-quality biopharma innovation," the report concluded.